MedTrace Logo

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

NCT00765323 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2013-09-27

No results posted yet for this study

Summary

Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.

Conditions

Interventions

DRUG

Octreotide Implant

84 mg octreotide subcutaneous implant for 6 months

DRUG

Sandostatin LAR Depot

Injections of Sandostatin LAR (dose range \~10-40 mg every 28 days)

Sponsors & Collaborators

  • Endo Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-02-28
Completion
2011-06-30

Countries

  • United States
  • Czechia
  • Germany
  • Hungary
  • Poland
  • Russia
  • Serbia
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765323 on ClinicalTrials.gov